# Natera, Inc. business and market developments

> Live situation record from CLSTR: https://clstr.news/situations/natera-inc-business-and-market-developments
> Updated: 2026-10-14T07:44:47.000Z. Sources: 4. Developments: 2.

Natera, Inc. has experienced growth in both its market valuation and strategic clinical applications. In September 2026, CEO Steven Chapman reported strong second-quarter performance, including nearly 40% year-over-year sales growth and record volumes for Signatera tests. During this period, Chapman executed a scheduled sale of approximately $545,000 in stock under a Rule 10b5-1 plan.

By October 2026, the company’s market outlook improved as TD Cowen raised its price target from $340.00 to $480.00. Natera also entered a strategic collaboration with TransCode Therapeutics to utilize Signatera in a Phase 2a study for colorectal cancer. This development follows the US FDA granting Breakthrough Device designation to Natera’s multi-cancer early detection blood test. Institutional investors continue to hold a dominant position in the company, owning 99.90% of its stock.

## Timeline

### 2026-10-14: Natera, Inc. sees price target hike and new strategic partnership

TD Cowen raised its price target for Natera, Inc. to $480.00 amid new strategic collaborations and significant institutional investment in the medical diagnostics firm.

2 sources. https://clstr.news/cluster/natera-inc-sees-price-target-hike-and-new-strategic-partnership

### 2026-09-18: Natera CEO Steven Chapman sells $545,000 in stock amid strong growth reports

Natera CEO Steven Chapman sold $545,000 in stock via a pre-scheduled plan, while company leadership reported record Signatera test volumes and strong growth at a Morgan Stanley healthcare conference.

2 sources. https://clstr.news/cluster/natera-ceo-steven-chapman-sells-545000-in-stock-amid-strong-growth-reports

---
Cite as: Natera, Inc. business and market developments. CLSTR, https://clstr.news/situations/natera-inc-business-and-market-developments